Drug Profile
Gastric cancer vaccine - OncoTherapy Science
Alternative Names: OTSGC-A24Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator OncoTherapy Science
- Developer Bristol-Myers Squibb; National University Hospital (Singapore); OncoTherapy Science
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide aptamers; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Gastric cancer
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Gastric-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Singapore (SC, Injection)
- 21 Dec 2021 OTSGC-A24 is still in phase I trial for Gastric cancer in Singapore
- 21 Dec 2021 Interim efficacy and safety data from a phase I trial in Gastric cancer released by OncoTherapy Sciences